REGENERON PHARMACEUTICALS, INC. reports

Company location: Tarrytown, NY
Fiscal year end: 31 December

REGENERON PHARMACEUTICALS, INC. has filed 2,452 SEC EDGAR filings since 26 Jul 1995

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 501-525 of 1,000 matching filings.

Per page

25

Current page

21

4

PRIMARY DOCUMENT

Filing date: 11 Apr 2022
Reporting date: 07 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 11 Apr 2022
Reporting date: 08 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 11 Apr 2022
Reporting date: 07 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 07 Apr 2022
Reporting date: 05 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 04 Apr 2022
Reporting date: 01 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 04 Apr 2022
Reporting date: 01 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 04 Apr 2022
Reporting date: 31 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 04 Apr 2022
Reporting date: 01 Apr 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Apr 2022
Reporting date: 30 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Apr 2022
Reporting date: 30 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Apr 2022
Reporting date: 30 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Apr 2022
Reporting date: 31 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Apr 2022
Reporting date: 31 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 31 Mar 2022
Reporting date: 29 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 30 Mar 2022
Reporting date: 28 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 23 Mar 2022
Reporting date: 21 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 23 Mar 2022
Reporting date: 21 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 18 Mar 2022
Reporting date: 16 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 18 Mar 2022
Reporting date: 16 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 18 Mar 2022
Reporting date: 16 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 15 Mar 2022
Reporting date: 14 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 000-19034

FORM 8-K

Filing date: 08 Mar 2022
Reporting date: 02 Mar 2022
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 03 Mar 2022
Reporting date: 01 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 03 Mar 2022
Reporting date: 01 Mar 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

4

PRIMARY DOCUMENT

Filing date: 01 Mar 2022
Reporting date: 25 Feb 2022
SEC evidence: Open document Open filing
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .